schliessen

Filtern

 

Bibliotheken

Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)

Purpose Tumour hypoxia is thought to play a significant role in the outcome of solid tumour therapy. Positron emission tomography (PET) is the best-validated noninvasive technique able to demonstrate the presence of hypoxia in vivo. The locally developed PET tracer for imaging hypoxia, 1-α- d -(5-de... Full description

Journal Title: European journal of nuclear medicine and molecular imaging 2009, Vol.36 (10), p.1565-1573
Main Author: Postema, Ernst J
Other Authors: McEwan, Alexander J. B , Riauka, Terence A , Kumar, Piyush , Richmond, Dacia A , Abrams, Douglas N , Wiebe, Leonard I
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Berlin/Heidelberg: Springer-Verlag
ID: ISSN: 1619-7070
Link: https://www.ncbi.nlm.nih.gov/pubmed/19430784
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_734072420
title: Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)
format: Article
creator:
  • Postema, Ernst J
  • McEwan, Alexander J. B
  • Riauka, Terence A
  • Kumar, Piyush
  • Richmond, Dacia A
  • Abrams, Douglas N
  • Wiebe, Leonard I
subjects:
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Non-Small-Cell Lung - diagnostic imaging
  • Carcinoma, Small Cell - diagnostic imaging
  • Carcinoma, Squamous Cell - diagnostic imaging
  • Cardiology
  • Female
  • Fluorine Radioisotopes
  • Glioma - diagnostic imaging
  • Head and Neck Neoplasms - diagnostic imaging
  • Humans
  • Hypoxia - diagnostic imaging
  • Imaging
  • Lung Neoplasms - diagnostic imaging
  • Lymphoma - diagnostic imaging
  • Male
  • Medicine
  • Medicine & Public Health
  • Middle Aged
  • Neoplasms - diagnostic imaging
  • Nitroimidazoles
  • Nuclear Medicine
  • Oncology
  • Original Article
  • Orthopedics
  • Positron-Emission Tomography
  • Radiology
  • Radiopharmaceuticals
  • Young Adult
ispartof: European journal of nuclear medicine and molecular imaging, 2009, Vol.36 (10), p.1565-1573
description: Purpose Tumour hypoxia is thought to play a significant role in the outcome of solid tumour therapy. Positron emission tomography (PET) is the best-validated noninvasive technique able to demonstrate the presence of hypoxia in vivo. The locally developed PET tracer for imaging hypoxia, 1-α- d -(5-deoxy-5-[ 18 F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18 F-FAZA), has been shown to accumulate in experimental models of tumour hypoxia and to clear rapidly from the circulation and nonhypoxic tissues. The safety and general biodistribution patterns of this radiopharmaceutical in patients with squamous cell carcinoma of the head and neck (HNSCC), small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC), malignant lymphoma, and high-grade gliomas, were demonstrated in this study. Methods Patients with known primary or suspected metastatic HNSCC, SCLC or NSCLC, malignant lymphoma or high-grade gliomas were dosed with 5.2 MBq/kg of 18 F-FAZA, then scanned 2–3 h after injection using a PET or PET/CT scanner. Images were interpreted by three experienced nuclear medicine physicians. The location and relative uptake scores (graded 0 to 4) of normal and abnormal 18 F-FAZA biodistribution patterns, the calculated tumour-to-background (T/B) ratio, and the maximum standardized uptake value were recorded. Results Included in the study were 50 patients (32 men, 18 women). All seven patients with high-grade gliomas showed very high uptake of 18 F-FAZA in the primary tumour. In six out of nine patients with HNSCC, clear uptake of 18 F-FAZA was observed in the primary tumour and/or the lymph nodes in the neck. Of the 21 lymphoma patients (15 with non-Hodgkin’s lymphoma and 6 with Hodgkin’s disease), 3 demonstrated moderate lymphoma-related uptake. Of the 13 lung cancer patients (12 NSCLC, 1 SCLC), 7 had increased 18 F-FAZA uptake in the primary lung tumour. No side effects of the administration of 18 F-FAZA were observed. Conclusion This study suggests that 18 F-FAZA may be a very useful radiopharmaceutical to image hypoxia in the tumour types selected. Especially the high uptake by gliomas was encouraging. Given the good imaging properties, including acceptable T/B ratios in the tumour categories studied, 18 F-FAZA could be considered as a very promising agent for assessing the hypoxic fraction of these tumour types.
language: eng
source:
identifier: ISSN: 1619-7070
fulltext: no_fulltext
issn:
  • 1619-7070
  • 1619-7089
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.5516105
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_cross
recordidTN_cdi_proquest_miscellaneous_734072420
sourceformatXML
sourcesystemPC
sourcerecordid734072420
originalsourceidFETCH-LOGICAL-c2485-147e6ff3866ce190e8c9ffe4924a7efabb2976cf4f9bea2eda33ae5f9f7f2d080
addsrcrecordideNp9kMFu1DAQhq2qiJbCA_RS5db2YBg7TmwfVxULlSpxgQsIWU4y3rryxls7kbq8FS_CM-HVrorEoZeZOfz_J81HyDmD9wxAfsgAvNEUQFPGGkGbI3LKWqapBKWPn28JJ-RNzg8ATHGlX5MTpkUNUolTMt2OfvI2VAnzHKZcRVfdbzfxydvKr-3Kj6tqzrvJ6J_fdKBXDR0wPm1pQ38wtfxJXZhjijbZzo_RzcmOMW_DNeW0kFP0az_YXzFgdVXidLn4vrh-S145GzK-O-wz8m358evNZ3r35dPtzeKO9lyohjIhsXWuVm3bI9OAqtfOodBcWInOdh3Xsu2dcLpDy3GwdW2xcdpJxwdQcEYu99xNio8z5smsfe4xBDtinLORtQDJBYeSZPtkn2LOCZ3ZpPJ-2hoGZufa7F2b4trsXJumdC4O9Llb4_CvcZBbAvI_aO8nO_k4Tsn68CKa75u5QMcVJvMQ5zQWVy-U_gKWwpwD
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid734072420
display
typearticle
titleInitial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)
creatorPostema, Ernst J ; McEwan, Alexander J. B ; Riauka, Terence A ; Kumar, Piyush ; Richmond, Dacia A ; Abrams, Douglas N ; Wiebe, Leonard I
creatorcontribPostema, Ernst J ; McEwan, Alexander J. B ; Riauka, Terence A ; Kumar, Piyush ; Richmond, Dacia A ; Abrams, Douglas N ; Wiebe, Leonard I
descriptionPurpose Tumour hypoxia is thought to play a significant role in the outcome of solid tumour therapy. Positron emission tomography (PET) is the best-validated noninvasive technique able to demonstrate the presence of hypoxia in vivo. The locally developed PET tracer for imaging hypoxia, 1-α- d -(5-deoxy-5-[ 18 F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18 F-FAZA), has been shown to accumulate in experimental models of tumour hypoxia and to clear rapidly from the circulation and nonhypoxic tissues. The safety and general biodistribution patterns of this radiopharmaceutical in patients with squamous cell carcinoma of the head and neck (HNSCC), small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC), malignant lymphoma, and high-grade gliomas, were demonstrated in this study. Methods Patients with known primary or suspected metastatic HNSCC, SCLC or NSCLC, malignant lymphoma or high-grade gliomas were dosed with 5.2 MBq/kg of 18 F-FAZA, then scanned 2–3 h after injection using a PET or PET/CT scanner. Images were interpreted by three experienced nuclear medicine physicians. The location and relative uptake scores (graded 0 to 4) of normal and abnormal 18 F-FAZA biodistribution patterns, the calculated tumour-to-background (T/B) ratio, and the maximum standardized uptake value were recorded. Results Included in the study were 50 patients (32 men, 18 women). All seven patients with high-grade gliomas showed very high uptake of 18 F-FAZA in the primary tumour. In six out of nine patients with HNSCC, clear uptake of 18 F-FAZA was observed in the primary tumour and/or the lymph nodes in the neck. Of the 21 lymphoma patients (15 with non-Hodgkin’s lymphoma and 6 with Hodgkin’s disease), 3 demonstrated moderate lymphoma-related uptake. Of the 13 lung cancer patients (12 NSCLC, 1 SCLC), 7 had increased 18 F-FAZA uptake in the primary lung tumour. No side effects of the administration of 18 F-FAZA were observed. Conclusion This study suggests that 18 F-FAZA may be a very useful radiopharmaceutical to image hypoxia in the tumour types selected. Especially the high uptake by gliomas was encouraging. Given the good imaging properties, including acceptable T/B ratios in the tumour categories studied, 18 F-FAZA could be considered as a very promising agent for assessing the hypoxic fraction of these tumour types.
identifier
0ISSN: 1619-7070
1EISSN: 1619-7089
2DOI: 10.1007/s00259-009-1154-5
3PMID: 19430784
languageeng
publisherBerlin/Heidelberg: Springer-Verlag
subjectAdolescent ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung - diagnostic imaging ; Carcinoma, Small Cell - diagnostic imaging ; Carcinoma, Squamous Cell - diagnostic imaging ; Cardiology ; Female ; Fluorine Radioisotopes ; Glioma - diagnostic imaging ; Head and Neck Neoplasms - diagnostic imaging ; Humans ; Hypoxia - diagnostic imaging ; Imaging ; Lung Neoplasms - diagnostic imaging ; Lymphoma - diagnostic imaging ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasms - diagnostic imaging ; Nitroimidazoles ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Positron-Emission Tomography ; Radiology ; Radiopharmaceuticals ; Young Adult
ispartofEuropean journal of nuclear medicine and molecular imaging, 2009, Vol.36 (10), p.1565-1573
rightsSpringer-Verlag 2009
lds50peer_reviewed
citedbyFETCH-LOGICAL-c2485-147e6ff3866ce190e8c9ffe4924a7efabb2976cf4f9bea2eda33ae5f9f7f2d080
citesFETCH-LOGICAL-c2485-147e6ff3866ce190e8c9ffe4924a7efabb2976cf4f9bea2eda33ae5f9f7f2d080
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19430784$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Postema, Ernst J
1McEwan, Alexander J. B
2Riauka, Terence A
3Kumar, Piyush
4Richmond, Dacia A
5Abrams, Douglas N
6Wiebe, Leonard I
title
0Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)
1European journal of nuclear medicine and molecular imaging
addtitle
0Eur J Nucl Med Mol Imaging
1Eur J Nucl Med Mol Imaging
descriptionPurpose Tumour hypoxia is thought to play a significant role in the outcome of solid tumour therapy. Positron emission tomography (PET) is the best-validated noninvasive technique able to demonstrate the presence of hypoxia in vivo. The locally developed PET tracer for imaging hypoxia, 1-α- d -(5-deoxy-5-[ 18 F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18 F-FAZA), has been shown to accumulate in experimental models of tumour hypoxia and to clear rapidly from the circulation and nonhypoxic tissues. The safety and general biodistribution patterns of this radiopharmaceutical in patients with squamous cell carcinoma of the head and neck (HNSCC), small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC), malignant lymphoma, and high-grade gliomas, were demonstrated in this study. Methods Patients with known primary or suspected metastatic HNSCC, SCLC or NSCLC, malignant lymphoma or high-grade gliomas were dosed with 5.2 MBq/kg of 18 F-FAZA, then scanned 2–3 h after injection using a PET or PET/CT scanner. Images were interpreted by three experienced nuclear medicine physicians. The location and relative uptake scores (graded 0 to 4) of normal and abnormal 18 F-FAZA biodistribution patterns, the calculated tumour-to-background (T/B) ratio, and the maximum standardized uptake value were recorded. Results Included in the study were 50 patients (32 men, 18 women). All seven patients with high-grade gliomas showed very high uptake of 18 F-FAZA in the primary tumour. In six out of nine patients with HNSCC, clear uptake of 18 F-FAZA was observed in the primary tumour and/or the lymph nodes in the neck. Of the 21 lymphoma patients (15 with non-Hodgkin’s lymphoma and 6 with Hodgkin’s disease), 3 demonstrated moderate lymphoma-related uptake. Of the 13 lung cancer patients (12 NSCLC, 1 SCLC), 7 had increased 18 F-FAZA uptake in the primary lung tumour. No side effects of the administration of 18 F-FAZA were observed. Conclusion This study suggests that 18 F-FAZA may be a very useful radiopharmaceutical to image hypoxia in the tumour types selected. Especially the high uptake by gliomas was encouraging. Given the good imaging properties, including acceptable T/B ratios in the tumour categories studied, 18 F-FAZA could be considered as a very promising agent for assessing the hypoxic fraction of these tumour types.
subject
0Adolescent
1Adult
2Aged
3Aged, 80 and over
4Carcinoma, Non-Small-Cell Lung - diagnostic imaging
5Carcinoma, Small Cell - diagnostic imaging
6Carcinoma, Squamous Cell - diagnostic imaging
7Cardiology
8Female
9Fluorine Radioisotopes
10Glioma - diagnostic imaging
11Head and Neck Neoplasms - diagnostic imaging
12Humans
13Hypoxia - diagnostic imaging
14Imaging
15Lung Neoplasms - diagnostic imaging
16Lymphoma - diagnostic imaging
17Male
18Medicine
19Medicine & Public Health
20Middle Aged
21Neoplasms - diagnostic imaging
22Nitroimidazoles
23Nuclear Medicine
24Oncology
25Original Article
26Orthopedics
27Positron-Emission Tomography
28Radiology
29Radiopharmaceuticals
30Young Adult
issn
01619-7070
11619-7089
fulltextfalse
rsrctypearticle
creationdate2009
recordtypearticle
recordideNp9kMFu1DAQhq2qiJbCA_RS5db2YBg7TmwfVxULlSpxgQsIWU4y3rryxls7kbq8FS_CM-HVrorEoZeZOfz_J81HyDmD9wxAfsgAvNEUQFPGGkGbI3LKWqapBKWPn28JJ-RNzg8ATHGlX5MTpkUNUolTMt2OfvI2VAnzHKZcRVfdbzfxydvKr-3Kj6tqzrvJ6J_fdKBXDR0wPm1pQ38wtfxJXZhjijbZzo_RzcmOMW_DNeW0kFP0az_YXzFgdVXidLn4vrh-S145GzK-O-wz8m358evNZ3r35dPtzeKO9lyohjIhsXWuVm3bI9OAqtfOodBcWInOdh3Xsu2dcLpDy3GwdW2xcdpJxwdQcEYu99xNio8z5smsfe4xBDtinLORtQDJBYeSZPtkn2LOCZ3ZpPJ-2hoGZufa7F2b4trsXJumdC4O9Llb4_CvcZBbAvI_aO8nO_k4Tsn68CKa75u5QMcVJvMQ5zQWVy-U_gKWwpwD
startdate20090509
enddate20090509
creator
0Postema, Ernst J
1McEwan, Alexander J. B
2Riauka, Terence A
3Kumar, Piyush
4Richmond, Dacia A
5Abrams, Douglas N
6Wiebe, Leonard I
generalSpringer-Verlag
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
87X8
sort
creationdate20090509
titleInitial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)
authorPostema, Ernst J ; McEwan, Alexander J. B ; Riauka, Terence A ; Kumar, Piyush ; Richmond, Dacia A ; Abrams, Douglas N ; Wiebe, Leonard I
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c2485-147e6ff3866ce190e8c9ffe4924a7efabb2976cf4f9bea2eda33ae5f9f7f2d080
rsrctypearticles
prefilterarticles
languageeng
creationdate2009
topic
0Adolescent
1Adult
2Aged
3Aged, 80 and over
4Carcinoma, Non-Small-Cell Lung - diagnostic imaging
5Carcinoma, Small Cell - diagnostic imaging
6Carcinoma, Squamous Cell - diagnostic imaging
7Cardiology
8Female
9Fluorine Radioisotopes
10Glioma - diagnostic imaging
11Head and Neck Neoplasms - diagnostic imaging
12Humans
13Hypoxia - diagnostic imaging
14Imaging
15Lung Neoplasms - diagnostic imaging
16Lymphoma - diagnostic imaging
17Male
18Medicine
19Medicine & Public Health
20Middle Aged
21Neoplasms - diagnostic imaging
22Nitroimidazoles
23Nuclear Medicine
24Oncology
25Original Article
26Orthopedics
27Positron-Emission Tomography
28Radiology
29Radiopharmaceuticals
30Young Adult
toplevelpeer_reviewed
creatorcontrib
0Postema, Ernst J
1McEwan, Alexander J. B
2Riauka, Terence A
3Kumar, Piyush
4Richmond, Dacia A
5Abrams, Douglas N
6Wiebe, Leonard I
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7MEDLINE - Academic
jtitleEuropean journal of nuclear medicine and molecular imaging
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Postema, Ernst J
1McEwan, Alexander J. B
2Riauka, Terence A
3Kumar, Piyush
4Richmond, Dacia A
5Abrams, Douglas N
6Wiebe, Leonard I
formatjournal
genrearticle
ristypeJOUR
atitleInitial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)
jtitleEuropean journal of nuclear medicine and molecular imaging
stitleEur J Nucl Med Mol Imaging
addtitleEur J Nucl Med Mol Imaging
date2009-05-09
risdate2009
volume36
issue10
spage1565
epage1573
pages1565-1573
issn1619-7070
eissn1619-7089
abstractPurpose Tumour hypoxia is thought to play a significant role in the outcome of solid tumour therapy. Positron emission tomography (PET) is the best-validated noninvasive technique able to demonstrate the presence of hypoxia in vivo. The locally developed PET tracer for imaging hypoxia, 1-α- d -(5-deoxy-5-[ 18 F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18 F-FAZA), has been shown to accumulate in experimental models of tumour hypoxia and to clear rapidly from the circulation and nonhypoxic tissues. The safety and general biodistribution patterns of this radiopharmaceutical in patients with squamous cell carcinoma of the head and neck (HNSCC), small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC), malignant lymphoma, and high-grade gliomas, were demonstrated in this study. Methods Patients with known primary or suspected metastatic HNSCC, SCLC or NSCLC, malignant lymphoma or high-grade gliomas were dosed with 5.2 MBq/kg of 18 F-FAZA, then scanned 2–3 h after injection using a PET or PET/CT scanner. Images were interpreted by three experienced nuclear medicine physicians. The location and relative uptake scores (graded 0 to 4) of normal and abnormal 18 F-FAZA biodistribution patterns, the calculated tumour-to-background (T/B) ratio, and the maximum standardized uptake value were recorded. Results Included in the study were 50 patients (32 men, 18 women). All seven patients with high-grade gliomas showed very high uptake of 18 F-FAZA in the primary tumour. In six out of nine patients with HNSCC, clear uptake of 18 F-FAZA was observed in the primary tumour and/or the lymph nodes in the neck. Of the 21 lymphoma patients (15 with non-Hodgkin’s lymphoma and 6 with Hodgkin’s disease), 3 demonstrated moderate lymphoma-related uptake. Of the 13 lung cancer patients (12 NSCLC, 1 SCLC), 7 had increased 18 F-FAZA uptake in the primary lung tumour. No side effects of the administration of 18 F-FAZA were observed. Conclusion This study suggests that 18 F-FAZA may be a very useful radiopharmaceutical to image hypoxia in the tumour types selected. Especially the high uptake by gliomas was encouraging. Given the good imaging properties, including acceptable T/B ratios in the tumour categories studied, 18 F-FAZA could be considered as a very promising agent for assessing the hypoxic fraction of these tumour types.
copBerlin/Heidelberg
pubSpringer-Verlag
pmid19430784
doi10.1007/s00259-009-1154-5